BPB Reports

Paper Details

BPB Reports
Vol. 3 No. 2 p.76-79 2020
Anti-Metastatic Effects of Curcumin Analogues in a Mouse Breast Cancer Model
  • Yoshihiro Hayakawa (Institute of Natural Medicine, University of Toyama / haya@inm.u-toyama.ac.jp)
Sisca Ucche 1) 2) , Retno Murwanti 2) , Ritmaleni 2) , Yoshihiro Hayakawa 1)
1) Institute of Natural Medicine, University of Toyama , 2) Faculty of Pharmacy, Universitas Gadjah Mada
Received: January 29, 2020;   Accepted: April 02, 2020;   Released: April 10, 2020
Keywords: cancer, metastasis, curcumin, nuclear factor kappa B

Curcumin is a polyphenol compound derived from the roots of Curcuma longa. Although the biological activities of curcumin, such as its anti-inflammatory, anti-oxidant, anti-microbial and anti-cancer effects, have been well applied, its poor chemical stability is a major problem. Pentagamavunon-0 (PGV-0) and Pentagamavunon- 1 (PGV-1) were developed as curcumin analogues with higher bioavailability; however, their anti-cancer activity has not yet been assessed. In this study, we evaluated the anti-metastatic activity of PGV-0 and PGV-1 in 4T1 breast cancer cells. Although both curcumin analogues demonstrated similar anti-proliferative effects to curcumin in 4T1 breast cancer cells, they did not inhibit nuclear factor kappa B (NF-ĸB) activity which is a well-defined molecular target of curcumin for its anti-cancer effects. As PGV-0 and PGV-1 exhibited stronger inhibition of the metastatic capacity in a 4T1 breast cancer model than curcumin, PGV-0 and PGV-1 may be promising curcumin analogues to target cancer metastasis having a distinct molecular mechanism from that of curcumin.